Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Vimkunya (PXVX0317) in Healthy Adults and Adolescents
NCT05072080Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CHIKV VLP vaccine in chikungunya virus infection, sponsored by Bavarian Nordic. Started Sep 2021; status: completed.
02
Drugs
CHIKV VLP vaccine
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT05072080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072080.